Explore

FDA Scrutiny on Clinical Trial Extension Studies Intensifies for Long-Term Drug Safety

FDA Scrutiny on Clinical Trial Extension Studies Intensifies for Long-Term Drug Safety

The U.S. Food and Drug Administration (FDA) is increasing its focus on the necessity of extension studies in clinical trials, particularly for chronic diseases, oncology, and gene therapies. A recent JAMA analysis highlights that most pivotal trials are designed to measure primary endpoints at fixed timepoints, often failing to assess sustained treatment benefits or detect rare, delayed adverse events that may manifest years after initial approval. This gap in data collection can lead to an inadequate understanding of a drug's long-term safety and efficacy. The FDA's stance, aligning with ICH E1 guidelines, emphasizes that long-term safety data should follow pivotal submissions, not precede them. Sponsors who do not pre-specify extension sample size requirements, retention strategies, and estimand frameworks before the pivotal trial begins risk negotiating with an insufficient dataset, potentially leading to constrained drug labels.

FDA Highlights Efforts to Expand Access to Medications for Opioid Use Disorder

FDA Highlights Efforts to Expand Access to Medications for Opioid Use Disorder

The U.S. Food and Drug Administration (FDA) is actively working to increase awareness and access to Medications for Opioid Use Disorder (MOUD) as a critical component in addressing the opioid crisis. Opioid Use Disorder (OUD) is a chronic medical condition affecting an estimated 4 million people aged 12 or older in the U.S. in 2025. The FDA emphasizes that safe and effective FDA-approved MOUDs are available for individuals with moderate-to-severe OUD, falling into three pharmacological categories: opioid agonist (methadone), partial agonist (buprenorphine), and antagonist (naltrexone). The agency is also supporting the development of new OUD treatments and educating the public and healthcare providers on available options.

FDA Proposes New Guidance to Accelerate Gene Therapies for Rare Diseases

FDA Proposes New Guidance to Accelerate Gene Therapies for Rare Diseases

The U.S. Food and Drug Administration (FDA) is shaping new guidance that could significantly speed up the development of gene therapies for rare diseases. This initiative, influenced by scientists in Philadelphia, aims to allow researchers to test a gene therapy platform against a sample of mutations. If successful, this would enable customization for individual patients without requiring a new clinical trial for each specific mutation. The FDA's new Rare Disease Framework Initiative emphasizes integrating patient perspectives early in the drug development cycle, moving away from traditional late-stage feedback. This framework champions the use of cutting-edge science, novel methods, and innovative clinical trial designs, including externally controlled studies, particularly for ultrarare diseases affecting fewer than 1,000 individuals. Under the Rare Disease Evidence Principles (RDEP) program, treatments for these ultrarare conditions may only need evidence from a single-arm trial, supplemented by strong ...

FDA Research Opportunity Focuses on Dose Selection for Inflammatory Bowel Disease Products

FDA Research Opportunity Focuses on Dose Selection for Inflammatory Bowel Disease Products

The U.S. Food and Drug Administration (FDA), specifically its Center for Drug Evaluation and Research (CDER), is offering a research opportunity focused on improving dose selection for products used in inflammatory bowel disease (IBD). This project, based in White Oak, Maryland, aims to support safer and more effective pediatric therapeutics by generating better evidence on dosing. The research will involve examining dose-selection strategies in clinical development programs for IBD products, comparing approved doses across age groups and indications, and studying how patient-specific factors like age, body size, disease activity, and immunogenicity influence pharmacokinetics, pharmacodynamics, and therapeutic response.

FDA Issues Warning Letter Against Unapproved Wharton's Jelly and Exosome Injections for Orthopedic Conditions

FDA Issues Warning Letter Against Unapproved Wharton's Jelly and Exosome Injections for Orthopedic Conditions

The U.S. Food and Drug Administration (FDA) has issued a warning letter to an IV hydration clinic for selling unapproved umbilical cord products, including Wharton's jelly, and exosome products as IV treatments. The FDA stated that these products are unapproved drugs and unlicensed biologics. The clinic's website advertised these products for conditions such as joint pain, arthritis pain, inflammation, damaged tissue, and hip pain. The FDA clarified that umbilical cord products, including Wharton's jelly, are not approved for any orthopedic condition like arthritis or joint pain, and there are currently no FDA-approved exosome products. The only legal use for these products in the U.S. for such conditions is within an FDA-cleared research study.

USPSTF Finds Insufficient Evidence for General Vitamin and Mineral Supplement Efficacy in Preventing Chronic Diseases

USPSTF Finds Insufficient Evidence for General Vitamin and Mineral Supplement Efficacy in Preventing Chronic Diseases

The U.S. Preventive Services Task Force (USPSTF) has concluded that there is insufficient evidence to determine the benefits and harms of most vitamin, mineral, and multivitamin supplements in preventing cardiovascular disease or cancer in generally healthy, non-pregnant adults. The 2022 recommendation specifically advises against the use of beta-carotene and vitamin E for this purpose. This finding emphasizes that supplements should be taken for a clear, specific reason, rather than as a general preventative measure. The USPSTF's stance does not apply to individuals with known nutritional deficiencies or specific dietary needs, where personalized supplement plans can still offer significant value. The guidance highlights the importance of consulting with a clinician to develop a tailored plan based on individual health history, diet, medications, and health goals, rather than relying on broad, unproven claims.

FDA Closes Investigation into Romaine Lettuce Salmonella Outbreak, Leaving Key Questions Unanswered

FDA Closes Investigation into Romaine Lettuce Salmonella Outbreak, Leaving Key Questions Unanswered

The Food and Drug Administration (FDA) has concluded its investigation into a Salmonella outbreak linked to romaine lettuce that sickened 43 people in the U.S. The agency closed the investigation with a brief 102-word notice, without disclosing the brand or grower of the implicated lettuce, nor the ages or locations of the affected patients. According to Food Safety News, by the time the FDA confirmed romaine lettuce as the source of the outbreak, the contaminated products were past their shelf life and no longer available for sale. No samples tested positive for the outbreak strain, despite the FDA's investigation including supply chain tracing, site visits, and sample testing.

Food Safety Advocate Proposes 'Project 2027' to Revitalize U.S. Food Safety Standards

Food Safety Advocate Proposes 'Project 2027' to Revitalize U.S. Food Safety Standards

A prominent food safety advocate has introduced 'Project 2027,' a comprehensive agenda aimed at revitalizing U.S. food safety. The advocate highlights a series of setbacks in federal food safety oversight over the past two years. These include the USDA withdrawing its Salmonella framework for raw poultry in April 2025, the CDC cutting its FoodNet pathogen surveillance system from eight to two pathogens in July 2025, and the Justice Department eliminating its Consumer Protection Branch in September 2025. Additionally, a law in November 2025 barred the FDA from enforcing its traceability rule before July 2028. These changes have coincided with significant outbreaks, such as the largest Cyclospora outbreak in U.S. history and botulism cases in infants linked to powdered formula, which federal rules do not require testing for. The advocate argues that many of these rollbacks were administrative and can be reversed.

FDA Warns Against Caffeine Vapes, Citing Lack of Safety Data and Unapproved Drug Status

FDA Warns Against Caffeine Vapes, Citing Lack of Safety Data and Unapproved Drug Status

The U.S. Food and Drug Administration (FDA) has issued warnings regarding caffeine vapes, classifying them as unapproved new drugs and raising significant safety concerns. These devices, often marketed as 'energy vapes' or 'diffusers,' heat a liquid containing caffeine and flavor into an aerosol for inhalation. Despite claims of being nicotine-free, the FDA highlights that there is almost no human research on their long-term safety. The agency has previously sent warning letters to manufacturers, stating that ingredients or impurities in inhaled products could trigger airway spasms and may be toxic to airway tissue. For instance, HELO caffeine vapes deliver approximately 1.3 mg of caffeine per 10 puffs, a significantly lower amount compared to a 12 oz cup of coffee, which contains 113 to 247 mg. The FDA emphasizes that no caffeine vape products are approved for medical use or for preventing or treating any condition, and their contents remain largely unknown and unregulated.

Whole Foods Market Recalls Ashwagandha Capsules Nationwide Due to Potential Salmonella Contamination

Whole Foods Market Recalls Ashwagandha Capsules Nationwide Due to Potential Salmonella Contamination

Whole Foods Market, in collaboration with Vitality Works Inc., has issued a nationwide recall for one lot of its 365 Whole Foods Market Standardized + Full Spectrum Blend Ashwagandha Capsules. The recall, announced on October 30, 2026, affects 120-count bottles of the supplement due to potential Salmonella contamination. The affected products, identified by batch number 2025-26227, UPC 9948252099, and an expiration date of October 13, 2028, were sold at Whole Foods Market stores across the U.S. and on Amazon.com between November 24, 2025, and October 20, 2026. The potential contamination was discovered during routine testing of a retail sample. As of the recall announcement, no illnesses have been reported in connection with this product. Consumers are advised not to consume the recalled capsules.

FDA Mandates Label Changes for GLP-1 Receptor Agonists Due to Potential Eye Condition Risk

FDA Mandates Label Changes for GLP-1 Receptor Agonists Due to Potential Eye Condition Risk

The U.S. Food and Drug Administration (FDA) is requiring manufacturers of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) medications to update their product labeling. This mandate stems from a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare but serious eye condition that can lead to acute, painless vision decrease in one eye, including permanent vision loss. The FDA's decision follows a comprehensive evaluation of clinical trial data, animal data, and postmarketing reports, including observational studies and case reports. While initial reports were challenging to interpret due to overlapping risk factors for NAION and conditions treated by GLP-1 RAs, further analysis indicated a potential association. The agency's meta-analysis of 126 clinical trials showed a NAION incidence rate of 6.4 events per 100,000 patient-years in GLP-1 RA users compared to 3.8 events per 100,000 patient-years in comparator groups. Additionally, a retrospective cohort study by the ...

Energy Drinks and Stimulant Supplements Linked to Acute Cardiovascular Events in Young Consumers

Energy Drinks and Stimulant Supplements Linked to Acute Cardiovascular Events in Young Consumers

New study results presented at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago indicate a disproportionate reporting of acute cardiovascular events associated with caffeine- and stimulant-containing energy drinks and dietary supplements. Investigators reviewed data from the U.S. Food and Drug Administration’s (FDA) Center for Food Safety and Applied Nutrition Adverse Event Reporting System. The analysis compared cardiovascular event reports for products containing caffeine, methylxanthines (like guarana and green tea extracts), sympathomimetics (such as yohimbine and ephedra), and popular caffeinated brands (including Celsius, Red Bull, Monster, and Rockstar) against other orally consumed products. The study found that 8 out of 10 cardiovascular outcomes achieved statistical signal thresholds, with the strongest signal for cardiac arrest, followed by myocardial infarction, ventricular arrhythmia, and palpitations. These findings suggest a significant link between these products and...